Cargando…

PCSK9 Gene E670G Polymorphism and Coronary Artery Disease: An Updated Meta-Analysis of 5,484 Subjects

Objective: Research has shown a possible relationship between the E670G polymorphism of the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene and an increased risk of coronary artery disease (CAD). However, there is no clear consensus on the subject because of conflicting results in the lit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yan-yan, Wang, Hui, Yang, Xin-xing, Geng, Hong-yu, Gong, Ge, Lu, Xin-zheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683799/ https://www.ncbi.nlm.nih.gov/pubmed/33244470 http://dx.doi.org/10.3389/fcvm.2020.582865

Ejemplares similares

E670G PCSK9 polymorphism in HeFH & CAD with diabetes: is the bridge to personalized therapy within reach?
por: Alieva, Rano, et al.
Publicado: (2023)

The E670G SNP in the PCSK9 gene is associated with polygenic hypercholesterolemia in men but not in women
por: Evans, David, et al.
Publicado: (2006)

Malaria severity: Possible influence of the E670G PCSK9 polymorphism: A preliminary case-control study in Malian children
por: Arama, Charles, et al.
Publicado: (2018)

Efficacy and safety of PCSK9 monoclonal antibodies: an evidence-based review and update
por: Kaddoura, Rasha, et al.
Publicado: (2020)

PCSK9 inhibitors for acute coronary syndrome: the era of early implementation
por: Chen, Hongzhen, et al.
Publicado: (2023)

Independent association of PCSK9 with platelet reactivity in subjects without statin or antiplatelet agents
por: Wang, Shuai, et al.
Publicado: (2022)

TGF-β1 Gene -509C/T Polymorphism and Coronary Artery Disease: An Updated Meta-Analysis Involving 11,701 Subjects
por: Li, Yan-yan, et al.
Publicado: (2017)

Physical activity to reduce PCSK9 levels
por: Tirandi, Amedeo, et al.
Publicado: (2022)

Impact of early PCSK9 inhibitor treatment on heart after percutaneous coronary intervention in patients with STEMI: Design and rationale of the PERFECT II trial
por: Xia, Jiachun, et al.
Publicado: (2022)

SUN-580 PCSK9 and Lp(a): Association Between PCSK9 Level and Larger Apo(a) Isoform Size in African-Americans and Caucasians
por: Byambaa, Enkhmaa, et al.
Publicado: (2020)

Structural Insight into the Two-Step Mechanism of PAI-1 Inhibition by Small Molecule TM5484
por: Sillen, Machteld, et al.
Publicado: (2021)

SUN-573 Use of PCSK9 Inhibitors Post-Transplant
por: Matthews, Juliana, et al.
Publicado: (2020)

Regulation of PCSK9 Expression and Function: Mechanisms and Therapeutic Implications
por: Xia, Xiao-dan, et al.
Publicado: (2021)

PCSK9/LDLR System and Rheumatoid Arthritis-Related Atherosclerosis
por: Arida, Aikaterini, et al.
Publicado: (2021)

Role of PCSK9 in Homocysteine-Accelerated Lipid Accumulation in Macrophages and Atherosclerosis in ApoE(−/−) Mice
por: Jin, Ping, et al.
Publicado: (2021)

An Update on the Role of PCSK9 in Atherosclerosis
por: Yurtseven, Ece, et al.
Publicado: (2020)

SUN-574 A1AT: Novel Inhibitor of Active PCSK9
por: Melendez, Quantil, et al.
Publicado: (2020)

PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
por: Luquero, Aureli, et al.
Publicado: (2021)

The Effect of Temperature on the Stability of PCSK-9 Monoclonal Antibody: An Experimental Study
por: Kongmalai, Tanawan, et al.
Publicado: (2021)

PCSK9 Inhibitors for the Management of Mitotane-Induced Hypercholesterolemia in Adrenocortical Carcinoma
por: Aurora, John A, et al.
Publicado: (2021)

SAT-576 Possible Involvement of Thyroid Function in PCSK9 Inhibitor Therapy
por: Iwabuchi, Masayasu
Publicado: (2020)

FRI101 Marked Reduction In Severe Resistant Hypertriglyceridemia On PCSK9 Inhibitor
por: Kaul, Sabrina, et al.
Publicado: (2023)

Anti‐PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care
por: Descamps, Olivier S., et al.
Publicado: (2017)

Interpreting the Findings From the Recent PCSK9 Monoclonal Antibody Cardiovascular Outcomes Trials
por: Wong, Nathan D., et al.
Publicado: (2019)

Effect of PCSK9 on atherosclerotic cardiovascular diseases and its mechanisms: Focus on immune regulation
por: Ma, Minglu, et al.
Publicado: (2023)

Advanced progress of the relationship between PCSK9 monoclonal antibodies and hyperglycemic adverse events
por: Zhang, Ruixing, et al.
Publicado: (2023)

Soluble Fas and the −670 Polymorphism of Fas in Lupus Nephritis
por: Bollain-y-Goytia, Juan José, et al.
Publicado: (2014)

Effects of PCSK9 inhibitors on coronary microcirculation, inflammation and cardiac function in patients with CHD after PCI: a protocol for systematic review and meta-analysis
por: Ye, Xuejiao, et al.
Publicado: (2023)

PCSK9 inhibitors for anti-inflammation in atherosclerosis: protocol for a systematic review and meta-analysis of randomised controlled trials
por: Luo, Jichang, et al.
Publicado: (2022)

EPCR Gene Ser219Gly Polymorphism and Venous Thromboembolism: A Meta-Analysis of 9,494 Subjects
por: Li, Yan-yan, et al.
Publicado: (2017)

Matrix metalloproteinase-9 Gene-1562C>T Gene Polymorphism and Coronary Artery Disease in the Chinese Han Population: A Meta-Analysis of 5468 Subjects
por: Li, Yan-Yan, et al.
Publicado: (2016)

Proteomics and Lipidomics to unveil the contribution of PCSK9 beyond cholesterol lowering: a narrative review
por: Gianazza, Erica, et al.
Publicado: (2023)

ADRB3 Gene Trp64Arg Polymorphism and Essential Hypertension: A Meta-Analysis Including 9,555 Subjects
por: Li, Yan-yan, et al.
Publicado: (2018)

Plasminogen Activator Inhibitor-1 Antagonist TM5484 Attenuates Demyelination and Axonal Degeneration in a Mice Model of Multiple Sclerosis
por: Pelisch, Nicolas, et al.
Publicado: (2015)

Correlation analysis between ApoM gene-promoter polymorphisms and coronary heart disease
por: Zhang, Yao, et al.
Publicado: (2016)

Associations Among PCSK9 Levels, Atherosclerosis-Derived Extracellular Vesicles, and Their miRNA Content in Adults With Obesity
por: Macchi, Chiara, et al.
Publicado: (2022)

PCSK9 Inhibitors Reduce PCSK9 and Early Atherogenic Biomarkers in Stimulated Human Coronary Artery Endothelial Cells
por: Zulkapli, Rahayu, et al.
Publicado: (2023)

Impact of conventional lipid-lowering therapy on circulating levels of PCSK9: protocol for a systematic review and meta-analysis of randomised controlled trials
por: Luo, Jichang, et al.
Publicado: (2022)

Dual Loading Antiplatelet Therapy in Patients With Acute Coronary Syndrome and High Bleeding Risk Undergoing Percutaneous Coronary Intervention: Findings From the Improving Care for Cardiovascular Disease in China Project
por: Yan, Yan, et al.
Publicado: (2022)

Association between FAS gene −670 A/G and −1377 G/A polymorphisms and the risk of autoimmune diseases: a meta-analysis
por: Yan, Hongwei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_q8bc5khhnlj55nr14rnhlbiljn